Elective Endovascular Treatment of Unruptured Intracranial Aneurysms

Background Elective endovascular treatment (EVT) of unruptured intracranial aneurysms (UIA) is a commonly used treatment modality. However, the appropriate post-procedure management is not well-defined. Methods This was a single-center, retrospective review of all adults undergoing EVT of UIA performed between January 1, 2010, and March 31, 2020. Patients with any current intracranial hemorrhage or clinical symptoms severe enough to warrant emergent intervention were excluded. Results Sixty-seven UIA were treated on 58 patients. The mean dome diameter was 6.6 mm (2-20, ±3.9), the most common parent vessel was the internal carotid artery (43.2%, 29/67), and sole flow diverter stents were the most common device used (46.2%, 31/67). Post-treatment, 43.2% (29/67) patients went to the neurocritical care unit (NCCU). The mean NCCU length of stay (LOS) was 1.07 days (range 1-4, ±0.5), and 96.6% (28/29) only spent one day in the NCCU. There were no (0%, 0/67) anesthesia-related procedural complications. One (1.5%, 1/67) intra-procedural complication was an aneurysm rupture during attempted coiling. There were five (7.4%, 5/67) post-procedural complications: two (3.0%, 2/67) groin hematomas, two (3.0%, 2/67) permanent neurologic events (left lower extremity hypoesthesia and left upper extremity hemiparesis), and one (1.5%, 1/67) temporary neurologic event (aphasia). Post-procedural complications were associated with longer hospital LOS (p=0.02), but not with longer NCCU LOS. No acute management changes occurred for the five patients that developed post-procedural complications. There were no (0%, 0/67) 30-day readmissions. Conclusion The overall incidence of post-procedure complications was low. In the future, a possible viable way to reduce hospital costs may involve utilizing a hospital unit that could closely monitor patients but only for a short period of time post-procedure.


Introduction
The estimated prevalence of unruptured intracranial aneurysms (UIAs) is 3.2% [1]. In clinical practice, the detection rate of these lesions has increased dramatically due to improved screening methods [2]. This has led to complex and ongoing debates about the optimal treatment modality for cerebral aneurysms [3,4]. However, clearly, there is a trend toward increased utilization of and spending on endovascular treatment (EVT) for UIAs [5,6]. This has brought about new challenges for effectively using health care resources. Unfortunately, few studies have examined post-EVT of UIAs clinical decision-making and neurologic intensive care unit (NCCU) admission [7][8][9][10][11].
The purpose of the study was to determine if NCCU admission post elective EVT of UIAs is warranted and whether to prevent complications entirely or hasten their detection. In addition, we sought to identify predictors of complications and determine if these complications were serious enough to warrant acute changes in clinical management or adversely affect patient outcomes. Finally, the aim of this study is to develop future post-EVT of UIA protocols to improve safety and reduce cost.

Materials And Methods
Inclusion criteria 1 1 This was a single-center, retrospective chart review that obtained Institutional Review Board (IRB) approval (IRB#7304-B5000343). All consecutive patients from the prospectively maintained institutional neuroendovascular registry were queried between January 1, 2010, and March 31, 2020. Inclusion criteria were age ≥18 years, presence of a UIA, and undergoing EVT. Exclusion criteria were any current intracranial hemorrhage or clinical symptoms severe enough to warrant emergent intervention.

Study variables
Clinical variables were defined as procedure date, age, gender, presence of symptoms pre-procedure, and any previous treatment. Lesion variables were defined as the number of aneurysms treated, largest aneurysm dome diameter, and aneurysm parent vessel origin. Treatment variables were defined as the type of intervention, type of device used, and the number of coils deployed. Post-treatment variables were defined as post-procedure anticoagulation medicine used, the post-procedure anti-platelet medication used, and unit disposition post-treatment. Discharge variables were defined as NCCU length of stay (LOS), hospital LOS, mortality, and whether the patient had 30-day readmission. Outcome measures are defined as anesthesia complications, intra-procedure complications, post-procedure complications, whether an additional intervention was performed, and if the complication warranted a change in the patient's hospital unit disposition.
The clinical, lesion and post-treatment variables were compared to discharge variables. Clinical, lesion, treatment, and discharge variables were compared to outcome measures. Post-treatment variables were compared to post-procedure complications. Outcome measures were compared to unit disposition posttreatment.

Statistical analysis
A sample of convenience was utilized. An a priori power analysis was not performed since consecutive patients were reviewed. Certain variables were dichotomized as either present or absent. If variables were not easily identified after reviewing the electronic medical record, they were considered null and excluded from the analysis. Independence was assumed between distinct procedures performed on the same patient. Descriptive analyses are reported as mean (range, ± 1 SD). Pearson's correlation coefficients were estimated for all comparisons, and significance was assessed using Monte Carlo simulation of Fisher's exact tests. A pvalue of ≤0.05 was considered statistically significant. Statistical analyses were performed using SAS (version 9.4; SAS Institute Inc).

Clinical variables
A total of 4,498 charts were screened dating back to January 1, 2010; however, the first UIA to meet inclusion criteria was treated on April 7, 2016. As a result, a total of 67 procedures met inclusion criteria that were performed on 58 patients ( Table 1).
Symptomatic UIA was positively correlated with increased NCCU LOS (r=0.48). However, this relationship was not significant (p=0.10). No associations were found with the age, gender, and previous EVT for NCCU LOS and hospital LOS.
There were no associations with procedure date, age, gender, whether symptomatic, or previous EVT for post-procedure complications.
There were no associations found between the number of UIA treated and NCCU or hospital LOS. Increasing UIA diameter was associated with longer NCCU LOS (p=0.03) but not hospital LOS. ACOM UIA was correlated with longer NCCU LOS (r=0.38); however, this relationship was not significant (p=0.15); ACOM UIA had significantly longer hospital LOS (p=0.04).
There was a correlation between the increasing number of UIA treated and the incidence of post-procedure complications (r=0.29). However, this relationship was not significant (p=0.09). There was no association between UIA diameter and post-procedural complications. ACOM UIA were more likely to develop postprocedural complications (p=0.02).
Utilization of FDS was correlated with shorter NCCU LOS (r=-0.32); however, this relationship was not significant (p=0.20). There were no associations found with the specific model device used or the number of coils deployed with NCCU LOS or hospital LOS.
There were no associations between the type of device used and the number of coils deployed with postprocedural complications.
Utilization of no antiplatelet medications and aspirin alone was correlated with a longer and shorter NCCU LOS (r=0.56, r=-0.38), respectively. However, these relationships were not significant (both p>0.07). There were no other associations between antiplatelet medications and NCCU LOS or hospital LOS.
There were no associations between antiplatelet medication usage and post-treatment disposition with post-procedural complications.
Post-procedural complications were associated with a longer hospital LOS (p=0.02), but not with a longer NCCU LOS.

Discussion
Opting for EVT of UIAs involves weighing the risk of immediate procedure-related complications against the risk of future rupture; the latter is supported by robust clinical data [12,13]. Results from the International Study of Unruptured Intracranial Aneurysms (ISUIA) trial and PHASES score have shown that not all UIA need to be immediately treated [12,13]. In our study, the mean age was 59.3 years old, the mean dome diameter was 6.6 mm, and 52.2% (35/67) of UIA were in the middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior communicating artery (PCOM), or posterior circulation vessels. While 16.4% (11/67) of the UIA treated had undergone the previous EVT, we did not record if there was previous subarachnoid hemorrhage (SAH). We also did not record the patient nationality or presence of hypertension. Opting for EVT of UIA may also be dictated by patient preference. Ultimately, we did not record the specific indication for EVT for a particular UIA.
An estimated 55% of all patients admitted to the NCCU are for monitoring alone. As many as 78% of these monitoring alone patients, as defined by their Acute Physiology, Age, Chronic Health Evaluation (APACHE) III score, are at low risk of receiving subsequent active life-supporting treatment [14]. Therefore it is crucial to identify which patients derive benefit from or absolutely require the level of monitoring and intervention that only an NCCU can provide. Critical care units are substantially more expensive than other hospital units, and their direct costs are rising [15,16]. Complications of EVT of UIAs are known but rare, making their indirect costs challenging to measure [17][18][19][20][21][22]. Hospital charges for EVT of UIAs often exceed those for surgical clipping [17]. However, Medicare reimbursement payments for aneurysm treatment are substantially lower than hospital costs [23]. This disparity, coupled with the increased utilization of EVT, presents a tremendous opportunity to improve post-procedural EVT of UIA care.
In 2008, the results of the Analysis of Treatment by Endovascular Approach of Nonruptured Aneurysms (ATENA) study were published [19]. In this landmark prospective international multicenter study of 649 patients harboring 1100 aneurysms undergoing elective EVT of UIA, the overall complication rate was 15.4% [19]. Since endovascular techniques and devices have evolved, the 30-day morbidity and mortality rates were 1.7% and 1.4%, respectively [19]. Contemporary meta-analyses have reported overall complication rates of 3.69-4.96% and 0.57% mortality rates, which aligns with our experience reported herein [17,18,20]. Previously identified predictors of complications include female gender, diabetes, hyperlipidemia, preexisting cardiac comorbidities, wide aneurysm neck >4 mm or a dome:neck ratio >1.5, posterior circulation aneurysms, stent-assisted coiling, and stenting alone [18].
Identifying the most likely precise timing of post-procedure complications may represent an opportunity to reduce morbidity and mortality. For example, Arias EJ et al. looked at 687 elective intracranial aneurysm coilings and found 74% of complications occurred within 4 hours of the procedure, 14.8% occurred within 4-12 hours, 3.7% happened within 12-24 hours, and 7.4% of complications occurred >24 hours after intervention [21]. Half of the complications that occurred <4 hours after intervention required treatment or resulted in permanent deficits, whereas those that occurred >12 hours after intervention were discharged home without deficits [21]. Furthermore, others have reported that 88% of complications occur within 24 hours of intervention [22]. In our study, the mean NCCU LOS was 1.07 days, and the admission to NCCU likely would not have hastened the detection of, reduced the morbidity associated with, or prevented the post-procedure complications.
Others have retrospectively examined elective EVT of UIA and proposed safe, cost-saving solutions [7][8][9][10][11] ( Table 4).  Based on their experience, many of these authors have concluded that routine post-EVT of UIA does not warrant automatic NCCU admission post-procedure [9][10][11]. However, we are unaware of any high-quality, prospective randomized studies comparing different hospital unit dispositions and outcomes. The principles of postoperative care include early identification and management of potential complications to reduce morbidity. At our institution, an anesthesiology team and neurointerventional proceduralist make a joint decision after treatment for patient disposition. Typically patients go to a post-anesthesia care unit (PACU) with 1:1 nursing to patient staffing for a period of 1-4 hours before going to a different hospital unit.

Article
There are several limitations to this study. First, this was a single-center retrospective study. Our sample size is also smaller as compared to other previously published papers. Second, we did not record the duration and type of anesthesia used, although no intra-procedure anesthesia complications occurred. Next, it is difficult to generalize the findings of this paper and others to facilities with varying staff and facility resources. Fourth, we only looked at electively treated UIA, and our results should not be generalized to ruptured aneurysms. Lastly, neuroendovascular treatment is an evolving field, which makes it challenging to generalize findings across rapidly changing techniques and devices.

Conclusions
In this study, we sought to scrutinize routine NCCU admission post-EVT of UIAs in regards to the incidence and treatment of procedural complications. The overall incidence of morbidity and mortality was low, and the presence of complications often did not change clinical management. Literature shows that predictors of complications are readily identifiable pre-intervention. Some patients could be delegated as low risk in the absence of intra-procedure complications such as hemorrhage or thrombosis. A possible, viable way to reduce hospital costs may involve utilizing a hospital unit that could closely monitor patients but only for a short period of time post-procedure. However, any protocol should be driven by patient safety and outcomes.

Additional Information Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Advocate Aurora Health Care issued approval IRB#7304-B5000343. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.